Indica
Backed by cutting edge technology, an uncompromising focus on ease-of-use and dedicated customer service, Indica Labs’ software and services are being used to make vital discoveries in pathology labs and research organizations around the world.
+1 (505) 492 0979
sales: info@indicalab.com
support: support@indicalab.com

Multiplex IHC

MULTIPLEX IHC

 

Product Overview

Indica Labs’ Multiplex IHC module separates up to five stains simultaneously within any cellular compartment (nucleus, cytoplasm or membrane) and can be used for a variety of IHC applications.  This module is ideally suited for applications in immuno-oncology where multiple markers are required to characterize distinct immune and tumor cell populations within the tissue.  Each cell is individually measured for cytoplasmic, nuclear, and/or membrane positivity.  The software also reports a variety of other statistics relating size and staining intensity metrics.

In the example above, a tissue core is stained with a brown (DAB) nuclear marker, blue membrane marker, pink/red cytoplasmic marker, and nuclear hematoxylin counterstain.  Cells are segmented using a combination of the two nuclear stains (hematoxylin and DAB) and one membrane stain (blue).  In the corresponding markup image, positive nuclei are colored brown and negative nuclei colored blue.  Similarly, cells identified as positive for the membrane marker are colored blue and cells identified as positive for cytoplasmic marker are pink.  Advanced staining courtesy of the Trev and Joyce Deeley Research Centre, BC Cancer Agency.

The Multiplex IHC module integrates seamlessly into the HALO® platform which is compatible with a number of third party systems and  file formats.

Contact info@indicalab.com for product demonstration and pricing information or upload some images for a free trial.

MULTIPLEX IHC

Indica Labs’ Multiplex IHC module separates up to five stains simultaneously within any cellular compartment (nucleus, cytoplasm or membrane) and can be used for a variety of IHC applications. This module is ideally suited for applications in immuno-oncology where multiple markers are required to characterize distinct immune and tumor cell populations within the tissue. Each cell is individually measured for cytoplasmic, nuclear, and/or membrane positivity. The software also reports a variety of other statistics relating size and staining intensity metrics.

In the example above, a tissue core is stained with a brown (DAB) nuclear marker, blue membrane marker, pink/red cytoplasmic marker, and nuclear hematoxylin counterstain. Cells are segmented using a combination of the two nuclear stains (hematoxylin and DAB) and one membrane stain (blue). In the corresponding markup image, positive nuclei are colored brown and negative nuclei colored blue. Similarly, cells identified as positive for the membrane marker are colored blue and cells identified as positive for cytoplasmic marker are pink. Advanced staining courtesy of the Trev and Joyce Deeley Research Centre, BC Cancer Agency.

HALO is compatible with a broad spectrum of image and digital slide formats.  Yours not on the list? Email us your requirements.

Non-proprietary (JPG, TIF)
Nikon (ND2)
3D Histech (MRXS)
Perkin Elmer (QPTIFF, component TIFF)
Olympus (VSI)
Hamamatsu (NDPI, NDPIS)
Aperio (SVS, AFI)
Zeiss (CZI)
Leica (SCN, LIF)
Philips (Requires Philips IMS)

Here are a few publications that cite use of our Multiplex IHC module.  Your publication not on the list?  Drop us an email to let us know about it!

TitleAuthorsYearJournalApplicationHALO Modules
Linking epigenetic signature and metabolic phenotype in IDH mutant and IDH wildtype diffuse gliomaBuran Y, Filipski K, Bernatz S, Baumgarten P, Roller B, Zinke J, Zeiner PS, Ilina E, Senft C, Ronellenfitsch MW, Plate KH, Bähr O, Hattingen E, Steinbach JP, Mittelbron M, Harter PN2020Neuropathology and Applied NeurobiologyNeuroscienceMultiplex IHC, TMA
Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancersChalabi M, Fanchi LF, Dijkstra KK, Van den Berg JG, Aalbers AG, Sikorska K, Lopez-Yurda M, Grootscholten C, Beets GL, Snaebjornsson P, Maas M, Mertz J, Veninga V, Bounova G, Broeks A, Beets-Tan RG, de Wijkerslooth TR, van Lent AU, Marsman HA, Nuijten E, Kok NF, Kuiper M, Verbeek WH, Kok M, Van Leerdam ME, Schumacher TN, Voest EE, Haanen JB2020Nature MedicineImmuno-oncologyMultiplex IHC, Serial Section
Computational image analysis of T-cell infiltrates in resectable gastric cancer: association with survival and molecular subtypesChalloner BR, von Loga K, Woolston A, Griffiths B, Sivamanoharan N, Semiannikova M, Newey A, Barber LJ, Mansfield D, Hewitt LC, Saito Y, Davarzani N, Starling N, Melcher A, Grabsch HI, Gerlinger M2020JNCI: Journal of the National Cancer InstituteImmuno-oncologyMultiplex IHC
Temporal and Spatial Heterogeneity of Host Response to SARS-CoV-2 Pulmonary InfectionDesai N, Neyaz A, Szabolcs A, Shih AR, Chen JH, Thapar V, Nieman LT, Solovyov A, Mehta A, Lieb DJ, Kulkarni AS, Jaicks C, Pinto CJ, Juric D, Chebib I, Colvin RB, Kim AY, Monroe R, Warren SE, Danaher P, Reeves JW, Gong J, Rueckert EH, Greenbaum BD, Hacohen N, Lagana SM, Rivera MN, Sholl LM, Stone JR, Ting DT, Deshpande V2020medRxivInfectious DiseaseMultiplex IHC
PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN Flaifel A, Xie W, Braun DA, Ficial M, Bakouny Z, Nassar AH, Jennings RB, Escudier B, George DJ, Motzer RJ, Morris MJ, Powles, Wang E, Huang Y, Freeman GJ, Choueiri TK, Signoretti S2019Clinical Cancer ResearchImmuno-oncologyMultiplex IHC
The effect of cyfluthrin on testis inhibin B in rats and the intervention of Lycium barbarum polysaccharideGuo X, Xie Y-X, Guo C, Wei J-L, Yang H-F2021Molecular & Cellular ToxicologyToxicologyMultiplex IHC
Receptor tyrosine kinase expression and phosphorylation in canine nasal carcinoma Hocker SA, Higginbotham ML, Schermerhorn T, Henningson J2017Research in Veterinary ScienceOncologyMultiplex IHC
Multiplexed Immunohistochemistry for Molecular and Immune Profiling in Lung Cancer—Just About
Ready for Prime-Time?
Hofman P, Badoual C, Henderson F, Berland L, Hamila M, Long-Mira E, Lassalle S, Roussel H, Hofman V, Tartour E, Ilié M2019CancersOncology, Immuno-oncology, ReviewClassifier, Multiplex IHC
FOXM1 contributes to treatment failure in acute myeloid leukemia Khan I, Halasi M, Patel A, Schultz R, Kalakota N, Chen Y-H, Aardsma N, Liu L, Crispino JD, Mahmud N, Frankfurt O, Gartel AL2018JCI InsightOncologyMultiplex IHC
Digital image analysis improves precision of PD‐L1 scoring in cutaneous melanoma Koelzer VH, Gisler A, Hanhart JC, Griss J, Wagner SN, Willi N, Cathomas G, Sachs M, Kempf W, Thommen DS, Mertz KD2018HistopathologyOncology, Immuno-oncologyClassifier, Multiplex IHC
Precision immunoprofiling by image analysis and artificial intelligenceKoelzer VH, Sirinukunwattana K, Rittscher J, Mertz KD2019Vichows ArchivReviewClassifier, Multiplex IHC, Spatial Analysis
The role of WNT10B in normal prostate gland development and prostate cancerMadueke I, Hu W-Y, Hu D, Swanson SM, Griend DV, Abern M, Prins GS2019The ProstateOncologyMultiplex IHC
Immuno-Interface Score to Predict Outcome in
Colorectal Cancer Independent of Microsatellite
Instability Status
Nestarenkaite A, Fadhil W, Ramusson A, Susanti S, Hadjimichael E, Laurinaviciene A, Ilyas M, Laurinavicius A2020CancersImmuno-oncologyClassifier, Multiplex IHC
Two distinct immunopathological profiles in autopsy lungs of COVID-19Nienhold R, Ciani Y, Koelzer VH, Tzankov A, Haslbauer JD, Menter T, Schwab N, Henkel M, Frank A, Zsikla V, Willi N, Kempf W, Hoyler T, Barbareschi M, Moch H, Tolnay M, Cathomas G, Demichelis F, Junt T, Mertz KD2020medRxivImmunology, Infectious DiseaseMultiplex IHC, HALO AI
A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma O’Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, MorrissetteJJD, Martinez-Lage M, Brem S, Maloney E, Shen A, Isaacs R, Mohan S, Plesa G, Lacey SF, Navenot J-M, Zheng Z, Levine BL, Okada H, June CH, Brogdon JL, Maus MV2017Science Translational MedicineOncology, Immuno-oncologyCytonuclear, Multiplex IHC
Assessment of associations between clinical and immune microenvironmental factors and tumor mutation burden in resected nonsmall cell lung cancer by applying machine learning to whole-slide imagesOno A, Terada Y, Kawata T, Serizawa M, Isaka M, Kawabata T, Imai T, Mori K, Muramatsu K, Hayashi I, Kenmotsu H, Oshima K, Urakami K, Nagashima T, Kusuhara M, Akiyama Y, Sugino T, Ohde Y, Yamaguchi K, Takahashi T T2020Cancer MedicineClassifier, Multiplex IHC, Serial Section
The KDM5A/RBP2 histone demethylase represses NOTCH signaling to sustain neuroendocrine differentiation and promote small cell lung cancer tumorigenesisOser MG, Sabet AH, Gao W, Chakraborty AA, Schinzel AC, Jennings RB, Fonseca R, Bonal DM, Booker MA, Flaifel A, Novak JS, Christensen VL, Zhang H, Herbert ZT, Tolstorukov MY, Buss EJ, Wong K-K, Bronson RT, Nguyen Q-D, Signoretti S, Kaelin Jr WG2019Genes & DevelopmentOncologyMultiplex IHC
Immunogradient Indicators for Antitumor Response Assessment by Automated Tumor-Stroma Interface Zone DetectionRasmusson A, Zilenaite D, Nestarenkaite A, Augulis R, Laurinaviciene A, Ostapenko V, Poskus T, Laurinavicius A2020The American Journal of PathologyMultiplex IHC, HALO AI
Physiologic serum 1,25 dihydroxyvitamin D is inversely associated with prostatic Ki67 staining in a diverse sample of radical prostatectomy patients Rosenberg A, NetteY OS, Gogana P, Sheikh U, Virgilia M, Macias V, Kajdacsy-Balla A, R Sharifi R, Kittles RA, Murphy AB2019Cancer Causes & ControlOncologyMultiplex IHC
An Antibody Targeting ICOS Increases Intratumoral
Cytotoxic to Regulatory T-cell Ratio and Induces Tumor
Regression
Sainson RCA, Thotakura AK, Kosmac M, Borhis G, Parveen N, Kimber R, Carvalho J, Henderson SJ, Pryke KL, Okell T, O'Leary S, Ball S, Van Krinks C, Gamand L, Taggart E, Pring EJ, Ali H, Craig H, Wong VWY, Liang Q, Rowlands RJ, Lecointre M, Campbell J, Kirby I, Melvin D, Germaschewski V, Oelmann E, Quaratino S, McCourt M2020Cancer Immunology ResearchImmuno-oncologyMultiplex IHC
Nuclear Glycogenolysis Modulates Histone Acetylation in Human Non-Small Cell Lung CancersSun RC, Dukhande VV, Zhou Z, Young LEA, Emanuelle S, Brainson CF, Gentry MS2019Cell MetabolismOncologyMultiplex IHC
A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade Thommen DS, Koelzer VH, Herzig P, Roller A, Trefny M, Dimeloe S, Kiialainen A, Hanhart J, Schil C, Hess C, Prince SS, Wiese M, Lardinois D, Ho P-C, Klein C, Karanikas V, Mertz KD, Schumacher TN, Zippelius A2018Nature MedicineOncology, Immuno-oncologyMultiplex IHC
Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamstersTostanoski LH, Wegmann F, Martinot AJ, Loos C, McMahan K, Mercado NB, Yu J, Chan CN, Bondoc S, Starke CE, Nekorchuk M, Busman-Sahay K, Piedra-Mora C, Wrijil LM, Ducat S, Custers J, Atyeo C, Fischinger S, Burke JS, Feldman J, Hauser BM, Caradonna TM, Bondzie EA, Dagotto G, Gebre MS, Jacob-Dolan C, Lin Z, Mahrokhian SH, Nampanya F, Nityanandam R, Pessaint L, Porto M, ALi V, Benetiene D, Tevi K, Andersen H, Lewis MG, Schmidt AG, Lauffenburger DA, Alter G, Estes JD, Schuitemaker H, Zahn R, Barouch DH2020Nature MedicineInfectious DiseaseArea Quantification, Multiplex IHC
Inducing and exploiting vulnerabilities for the treatment of liver cancerWang C, Vegna S, Jin H, Benedict B, Lieftink C, Ramirez C, de Oliveira RL, Morris B, Gadiot J, Wang W, du Chatinier A, Wang L, Gao D, Evers B, Jin G, Xue Z, Schepers A, Jochems F, Sanchez AM, Mainardi S, te Riele H, Beijersbergen RL, Qin W, Akkari L, Bernards R2019NatureOncologyMultiplex IHC

Use the form below to upload up to three images for us to analyze using HALO.  If the form does not display, please click here.